Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.63 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416383 | 1.00 | SIGMAR1 (0.63) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL4091905 | 0.83 | TAAR1 (0.59) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL15699472 | 0.81 | SLC6A4 (0.42) | SIGMAR1TAAR1SLC18A2SLC6A4KMT2A | |
| SCHEMBL13416759 | 0.81 | SIGMAR1 (0.50) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL30131242 | 0.79 | SLC6A2 (0.53) | SIGMAR1TAAR1SLC18A2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL28649749 | 0.79 | TAAR1 (0.53) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL22857424 | 0.79 | SIGMAR1 (0.53) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL20403618 | 0.78 | TAAR1 (0.52) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL19565108 | 0.78 | SIGMAR1 (0.47) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL14570166 | 0.77 | TAAR1 (0.52) | SIGMAR1TAAR1SLC18A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11858925-B2 | GAS41 inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858925-B2 | GAS41 inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220017509-A1 | GAS41 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | SIGMAR1 1154/4885TAAR1 661/4885SLC18A2 2378/4885 |
| US-11858925-B2 | GAS41 inhibitors and methods of use thereof | GAS6, HIF1AN, TMEM41B | SIGMAR1 4418/4885TAAR1 4538/4885SLC18A2 4817/4885 |
| US-20220017509-A1 | GAS41 INHIBITORS AND METHODS OF USE THEREOF | GAS6, HIF1AN, TMEM41B | SIGMAR1 4418/4885TAAR1 4538/4885SLC18A2 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.